Raymond James Financial
KYMR icon

Raymond James Financial’s Kymera Therapeutics KYMR Stock Holding History

Raymond James Financial’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$15.5M Buy
+135,584
New +$11.6M ﹤0.01% 1767
2025
Q3 		– Sell
-1,664
Closed -$72.6K – 5912
2025
Q2 		$72.6K Buy
+1,664
New +$57.3K ﹤0.01% 5018

Other funds holding KYMR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Raymond James Financial's KYMR Position: Q2 2026 in Review

Raymond James Financial opened a new position in Kymera Therapeutics (KYMR) in Q2 2026: 135,584 shares worth $15.5M. The stake represents ﹤0.01% of the portfolio and ranks #1767 among its holdings. This is a return to the name: Raymond James Financial previously reported a position in KYMR as recently as Q2 2025.

Raymond James Financial first reported a position in KYMR in Q2 2025 and has held it in 2 quarters since. 276 funds tracked by Wall St. Rank hold KYMR as of Q2 2026.

  • Raymond James Financial held 135,584 shares of Kymera Therapeutics worth $15.5M as of Q2 2026.
  • Kymera Therapeutics was a new Raymond James Financial position in Q2 2026.
  • Kymera Therapeutics made up ﹤0.01% of Raymond James Financial's portfolio in Q2 2026, its #1767 holding.
  • Raymond James Financial first reported a position in Kymera Therapeutics in Q2 2025 and has held it in 2 quarters since.
  • 276 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q2 2026.

Based on Raymond James Financial's 13F filing for Q2 2026, filed 14 Aug 2026.